Company

AstraZeneca (LSE:AZN)

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.

About AZN

Related Articles

Investing Videos

Is AstraZeneca Plc A Good Way To Play Emerging Markets?

VIDEO: One Fool weighs up the emerging-market potential of AstraZeneca plc (LON:AZN).

Read more »

Company Comment

Betting On AstraZeneca plc’s Drug Pipeline

What’s caused £41 billion drugs maker AstraZeneca plc (LON:AZN) to become afflicted by a seemingly interminable wasting disease?

Read more »

Investing Videos

A Closer Look At AstraZeneca plc

VIDEO: Two Fools analyse AstraZeneca plc (LON: AZN).

Read more »

Company Comment

Earnings Drop 16% At AstraZeneca Plc

Investing the future while revenues fall takes its toll on the bottom line at AstraZeneca plc (LON:AZN).

Read more »

Investing Articles

Why You Might Think Of Investing In This FTSE Underdog: AstraZeneca plc

AstraZeneca plc (LON: AZN) could be a contrarian investment opportunity.

Read more »

Investing Articles

Why Reinvesting Your Dividends Is The Best Decision You’ll Ever Make

Dividend reinvestment is a great way to achieve market beating returns without much effort.

Read more »

Company Comment

2 Big Problems For GlaxoSmithKline Plc

It's been a rough year for pharmaceutical giant GlaxoSmithKline plc (LON: GSK).

Read more »

Investing Articles

4 Ways AstraZeneca plc Will Continue To Lead The Biotechnology Sector

How does AstraZeneca plc (LON: AZN) compare to its sector peers?

Read more »

Investing Articles

Why I Hate AstraZeneca plc

Aside from its 5.6% yield, Harvey Jones finds little to love about AstraZeneca plc (LON: AZN).

Read more »

Investing Articles

4 Ways GlaxoSmithKline plc Will Continue To Lag The Biotechnology Sector

How does GlaxoSmithKline plc (LON: GSK) compare to its sector peers?

Read more »